Paratek Pharmaceuticals Inc (PRTK) was Reiterated by H.C. Wainwright to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 34 from a previous price target of $31 . H.C. Wainwright advised their investors in a research report released on Jun 17, 2016.
Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Robert W. Baird Initiated Paratek Pharmaceuticals Inc on May 13, 2016 to “Outperform”, Price Target of the shares are set at $30.Cantor Fitzgerald Resumed Paratek Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $27.
Paratek Pharmaceuticals Inc closed down -0.47 points or -2.78% at $16.42 with 79,277 shares getting traded on Wednesday. Post opening the session at $16.79, the shares hit an intraday low of $16.37 and an intraday high of $17.09 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 14, 2015, Evan Loh (President and CMO) purchased 2,300 shares at $16.83 per share price.
Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.